Argenx Se Stock News

Some of the stocks that may grab investor focus today are: Wall Street expects Carnival Corporation (NYSE: CCL) to report a quarterly loss at $1.27 per share on revenue of $1.34 billion before the

The recent approval of this drugmaker's first product is giving reasons to cheer now, but what about down the road?

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news. Among the regulatory decisions for the week, the Food and Drug Administration gave the green light to argenx SE''s (NASDAQ: ARGX ) efgartigimod for the treatment of generalized myasthenia gravis. AstraZeneca plc (NASDAQ: AZN ) and Amgen, Inc. (NASDAQ: AMGN ) announced an FDA nod for their Tezspire as a treatment option for severe asthma for those aged 12 years and older. Bristol-Myers Squibb Company ''s (NYSE: BMY ) Orencia was approved for the prophylactic treatment of acute graft-versus-host disease. Calliditas Therapeutics AB (publ) (NASDAQ: CALT ) scored an FDA win for Tarpeyo, the first-approved treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. Galera Therapeutics, Inc. (NASDAQ: Full story available on Benzinga.

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that its partner argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. These patients represent approximately 85% of the total gMG population 1 . With this regulatory milestone, VYVGART is the first and only FDA-approved neonatal Fc receptor (FcRn) blocker.

VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on t

BREDA, Netherlands--(BUSINESS WIRE)--Regulatory News: argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. These patients represent appro

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral COVID-19 Antiviral Treatmen

Michael Yee, Jefferies, on whether there's more M&A to come in the biotech space. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Pete Najarian and Karen Finerman.

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday. The Biopharma Analy

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday.

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple conference presentations

Analysts predict that argenx SE (NASDAQ:ARGX) will post earnings of ($5.06) per share for the current quarter, according to Zacks. Four analysts have made estimates for argenxs earnings. The highest EPS estimate is ($4.08) and the lowest is ($6.71). argenx reported earnings per share of ($4.20) during the same quarter last year, which suggests a []

Wells Fargo & Company MN lowered its position in argenx SE (NASDAQ:ARGX) by 12.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,611 shares of the companys stock after selling 3,506 shares during the period. Wells Fargo & Company MNs holdings []

argenx SE (NASDAQ:ARGX) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,000,000 shares, a growth of 32.7% from the October 31st total of 753,400 shares. Approximately 2.0% of the shares of the stock are short sold. Based on an []